United States

People: Senomyx Inc (SNMX.OQ)

SNMX.OQ on NASDAQ Stock Exchange Global Market

21 Oct 2016
Change (% chg)

$-0.03 (-1.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Poyhonen, John 

Mr. John W. Poyhonen has been appointed as President, Chief Executive Officer, Director of Senomyx Inc. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006, he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas. Mr. Poyhonen contributes his extensive knowledge of the company. In addition, as a result of his long tenure with the company in roles of increasing responsibility, Mr. Poyhonen contributes his leadership skills and financial and operational expertise.

Basic Compensation

Total Annual Compensation, USD 500,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,157,500
Fiscal Year Total, USD 2,657,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 37,600 72,180.00
Name Fiscal Year Total

Kent Snyder


John Poyhonen


Antony Rogers


Sharon Wicker


Jay Short


Daniel Stebbins

As Of  30 Dec 2014